Evidence map›Paper›PMID 34817733›Full record

Trial reportQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2022

Joint modelling with competing risks of dropout for longitudinal analysis of health-related quality of life in cancer clinical trials.

Benjamin Cuer, Thierry Conroy, Beata Juzyna, Sophie Gourgou, Caroline Mollevi, Célia Touraine

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00861094 (Phase II-III Study Comparing Radiochemotherapy With the FOLFOX Regimen Versus Radiochemotherapy With 5FU-cisplatin), which is not on this map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
1.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00861094 phase2 / phase3completednot on this map

Phase II-III Study Comparing Radiochemotherapy With the FOLFOX Regimen Versus Radiochemotherapy With 5FU-cisplatin (Herskovic Regimen) in First Line Treatment of Patients With Inoperable Oesophageal Cancer.

TypeinterventionalSponsorUNICANCERRan2008 to 2012Enrolled266ConditionsEsophageal CancerArmscisplatin, 5-FU, oxaliplatin, radiation therapy, Folinic Acid
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. A Framework for the Estimation of Quality-Adjusted Life-Years Using Joint Models of Longitudinal and Survival Data.Medical decision making : an international journal of the Society for Medical Decision Making · 2026
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Benjamin CuerBiometrics Unit, Montpellier Cancer Institute, 208, avenue des Apothicaires, 34298, Montpellier, France. cuerbenjamin@gmail.com.ORCID http://orcid.org/0000-0002-5634-0704
Thierry ConroyInstitut de Cancérologie de Lorraine, Department of Medical Oncology, Vandoeuvre-lès-Nancy, France.
Beata JuzynaFrench Federation of Comprehensive Cancer Centres, R&D UNICANCER, Paris, France.
Sophie GourgouBiometrics Unit, Montpellier Cancer Institute, 208, avenue des Apothicaires, 34298, Montpellier, France.
Caroline MolleviBiometrics Unit, Montpellier Cancer Institute, 208, avenue des Apothicaires, 34298, Montpellier, France.
Célia TouraineBiometrics Unit, Montpellier Cancer Institute, 208, avenue des Apothicaires, 34298, Montpellier, France.
Inserm · FRInstitut de Cancérologie de Lorraine · FRInstitut de Recherche en Cancérologie de Montpellier · FRUniCancer Group · FR

Funding

Region Occitanie Program "Allocation Doctorale 2017"SIRIC Montpellier Cancer Grant INCa_Inserm_DGOS_12553
6 · The paper itself

Abstract

purposeHealth-related quality of life (HRQoL) is an important endpoint in cancer clinical trials. Analysis of HRQoL longitudinal data is plagued by missing data, notably due to dropout. Joint models are increasingly receiving attention for modelling longitudinal outcomes and the time-to-dropout. However, dropout can be informative or non-informative depending on the cause.

methodsWe propose using a joint model that includes a competing risks sub-model for the cause-specific time-to-dropout. We compared a competing risks joint model (CR JM) that distinguishes between two causes of dropout with a standard joint model (SJM) that treats all the dropouts equally. First, we applied the CR JM and SJM to data from 267 patients with advanced oesophageal cancer from the randomized clinical trial PRODIGE 5/ACCORD 17 to analyse HRQoL data in the presence of dropouts unrelated and related to a clinical event. Then, we compared the models using a simulation study.

resultsWe showed that the CR JM performed as well as the SJM in situations where the risk of dropout was the same whatever the cause. In the presence of both informative and non-informative dropouts, only the SJM estimations were biased, impacting the HRQoL estimated parameters.

conclusionThe systematic collection of the reasons for dropout in clinical trials would facilitate the use of CR JMs, which could be a satisfactory approach to analysing HRQoL data in presence of both informative and non-informative dropout.

trial registrationThis study is registered with ClinicalTrials.gov, number NCT00861094.

Indexed as

NeoplasmsQuality of LifeComputer SimulationHumansLongitudinal StudiesModels, StatisticalPatient DropoutsClinical trialsCompeting risksHealth-related quality of lifeJoint modellingMissing dataOncology

Identifiers

PMID34817733
OpenAlexW3216326576

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.